教員業績データベース |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読なし |
表題 | Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. |
掲載誌名 | 正式名:Journal of gastroenterology 略 称:J Gastroenterol ISSNコード:1435-5922(Electronic)0944-1174(Linking) |
掲載区分 | 国外 |
巻・号・頁 | 52(9),pp.1031-40 |
著者・共著者 | Suzuki Yasuo, Motoya Satoshi, Hanai Hiroyuki, Hibi Toshifumi, Nakamura Shiro, Lazar Andreas, Robinson Anne Martin, Skup Martha, Mostafa Nael Mohamed, Huang Bidan, Thakkar Roopal, Watanabe Mamoru |
発行年月 | 2017/09 |
概要 | BACKGROUND:The 52-week safety and efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis were demonstrated in a placebo-controlled phase 2/3 trial. Data from patients who enrolled in the open-label extension study are presented.METHODS:Remission and response per the full Mayo score (FMS) and the partial Mayo score (PMS), remission per the Inflammatory Bowel Disease Questionnaire (IBDQ) score, corticosteroid-free remission, and mucosal healing were assessed up to week 196 (week 208 for remission/response per PMS) of adalimumab treatment in patients who received one or more doses of adalimumab with use of a hybrid nonresponder imputation (hNRI) method. |
DOI | 10.1007/s00535-017-1325-2 |
PMID | 28321512 |